Podcasts about improved outcomes

Today, on Framework Friday episode one, How to Craft Impactful User Stories for Improved Outcomes, we're diving into a powerful tool for defining "what done looks like": user stories.People:Users, customers, and ourselvesProcess:Crafting user storiesUsing the MoSCoW prioritization methodProgress:Defining "what done looks like." more effectivelyGodspeed y'all,Kevin

When it comes to childbirth, many expectant parents envision waiting for labor to begin naturally. However, recent research, including the groundbreaking ARRIVE Trial (A Randomized Trial of Induction Versus Expectant Management), has reshaped how medical professionals approach labor and delivery, particularly for first-time moms. The ARRIVE Trial studied over 6,000 first-time mothers with low-risk pregnancies. It compared outcomes for those induced at 39 weeks of pregnancy with those who waited for labor to begin spontaneously. The results challenged traditional assumptions about induction, revealing several compelling reasons why induction of labor might be recommended: 1. Lower Cesarean Delivery Rates Contrary to concerns that induction might increase the likelihood of cesarean delivery, the ARRIVE Trial found the opposite. Women induced at 39 weeks had a significantly lower rate of cesarean births (18.6%) compared to those who waited for spontaneous labor (22.2%). This finding is critical, as cesarean delivery carries higher risks of complications and a longer recovery period for the mother. 2. Improved Outcomes for Babies Inducing labor at 39 weeks was associated with better neonatal outcomes. Babies born to mothers in the induction group were less likely to require respiratory support or experience other complications. This is significant because it underscores the potential for induction to enhance both maternal and neonatal health. 3. Reduced Risks Associated with Post-Term Pregnancies While 39 weeks is considered full term, waiting for spontaneous labor can sometimes lead to pregnancies extending beyond 40 weeks. Post-term pregnancies carry increased risks of complications, including stillbirth and meconium aspiration. By opting for induction at 39 weeks, providers aim to mitigate these risks while ensuring the baby is delivered at an optimal time. 4. Enhanced Predictability for Families For many first-time parents, induction offers a level of predictability. Knowing when labor will begin can help families plan for childcare, work leave, and support during delivery. This logistical benefit is often a practical consideration in recommending induction. 5. Alignment with Modern Maternal-Fetal Care The ARRIVE Trial highlights a shift in how healthcare providers view induction. Rather than considering it only when medically necessary, induction at 39 weeks for first-time moms is increasingly seen as a proactive approach to optimize outcomes. Importantly, this recommendation is tailored to women with low-risk pregnancies who meet specific criteria, ensuring that induction is not overused. Things to Keep in Mind While the ARRIVE Trial has influenced many obstetric practices, it's essential to remember that each pregnancy is unique. The decision to induce labor should be based on a thorough evaluation of the mother's health, the baby's condition, and the preferences of the birthing person.   Other Episodes that related to this topic: Episode 10 - NatureBack Philopsphy Episoide 130 - Why Induction takes 24 hours or less   Your feedback is essential to us! We would love to hear from you. Please consider leaving us a review on your podcast platform or sending us an email at info@maternalresources.org. Your input helps us tailor our content to better serve the needs of our listeners. For additional resources and information, be sure to visit our website at Maternal Resources: https://www.maternalresources.org/. You can also connect with us on our social channels to stay up-to-date with the latest news, episodes, and community engagement: Twitter: https://twitter.com/integrativeob YouTube: https://www.youtube.com/maternalresources Instagram: https://www.instagram.com/integrativeobgyn/ Facebook: https://www.facebook.com/IntegrativeOB Thank you for being part of our community, and until next time, let's continue to support, uplift, and celebrate the incredible journey of working moms and parenthood. Together, we can create a more equitable and nurturing world for all.

The 154th episode of the Healthcare IT Today Podcast is sponsored by DrFirst, and this time we are talking about optimizing the medication journey from prescribing to adherence to improved outcomes with special guest host Colin Banas, MD, MHA, Chief Medical Officer at DrFirst! We kick this episode off by discussing what it takes now […]

Is the ‘Insurtech revolution' over? Max Drucker, CEO of Carpe Data and I explore this and other questions on this week's The Leadership in Insurance Podcast . We also discussed the refocus of Insurtech from revolution to measurable results using an evolutionary approach.

Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the University of Bielefeld in Germany, spoke with Oncology Times reporter Peter Goodwin about his group’s comparison of neoadjuvant therapy using the CROSS (41.4 Gy plus carboplatin/paclitaxel) regimen followed by surgery, with the use of an alternative protocol: perioperative FLOT (5-FU/ leucovorin/oxaliplatin/docetaxel) and surgery, in which chemotherapy is given both before and after curative surgery.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VGY865. CME/MOC credit will be available until June 4, 2025.Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VGY865. CME/MOC credit will be available until June 4, 2025.Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VGY865. CME/MOC credit will be available until June 4, 2025.Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VGY865. CME/MOC credit will be available until June 4, 2025.Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VGY865. CME/MOC credit will be available until June 4, 2025.Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VGY865. CME/MOC credit will be available until June 4, 2025.Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This episode of The TechLink Health Podcast digs deeper into the future of health from an organizational level and how companies are harnessing the power of deep technology to improve health outcomes at global scale. In the Pre-COVID era, many noted that the healthcare industry was primed for a major disruption, and then the pandemic hit, which acted as a catalyst for change within the industry and a leap into the future of care with respects to digital health solutions such as tele-health, remote patient monitoring alongside deep tech such as AI and algorithmic driven tools. This shift in the industry is happening in parallel to an increased focus on Value Based Care initiatives such as outcome-based payment models, patient-centered care models, improved quality of metrics alongside increases in preventive services and wellness programs. One of the complexities associated with this transformation is the organizational and cultural shifts that are driving health entities and organizations to be more agile in the quest to implement change and take advantage of the emerging era of deep tech. The future of global health is promising, but the journey to get there is an intensive effort driven by the coordination of key players across the spectrum of large organizations, public sector partners, and fast-moving startups. Here to talk about all of this and more is this episode's guest, Ritwik Batabyal, Chief Technology and Innovation Officer for Mastek, an enterprise digital and cloud transformation partner that engineers excellence for customers across industries, including healthcare and life sciences, spanning 40 countries, including the UK, US, Europe, the Middle East, and Asia Pacific. Ritwik's role is directly tied to enabling relevant new disruptive technologies and creating monetization strategies at the intersections of Data and AI across industries, while crafting long-term technology innovation roadmaps and building partnerships with start-ups & external innovation ecosystems. Listen in with us to learn more about the fundamental shift to Value-Based Care and the deep technologies that are helping to drive the transformation. Other insights range from how collaboration between larger corporations and nimble startups can expand the innovation curve, to key areas of focus for creating a more equitable future in healthcare, to how the integration of AI-tech with IoT devices is helping to evolve precision medicine. For more details visit TechLink Health on the web or connect with Ritwik on LinkedIn. This episode was hosted by David Sanchez, RN, Medical SEO Consultant and Dr. Sarah Samaan. The episode points to several references with links below:

The post-pandemic years have seen a rise in the public's desire to experience nature in person. This has sparked an opportunity for coaches to explore a significant trend in the coaching industry – integrating nature into coaching sessions.  Let's explore how nature integrates naturally with coaching, and how coaches can use nature in their own sessions. Everything Life Coaching is brought to you by Lumia-- at Lumia, we train and certify impact-driven coaches, making sure they've got all they need to build a business they love and transform lives, on their terms. Become a life coach, and make a bigger impact on the world around you! Schedule a call with us today to discuss your future as a coach. Music in this episode is by Cody Martin, used under a creative commons license. The Everything Life Coaching Podcast is Produced and Audio Engineered by Amanda Meyncke.

I'm thrilled to chat with you about some of the digital marketing strategies we've been unpacking on the show. It's no secret that vet practices are hitting some bumps in the digital road, with ad costs going up and client attention spans shrinking. But I've got your back! In a recent episode, we dove into this headfirst, and I'm here to break it down for you with some actionable advice. Let's kick things off with your value proposition—this is your secret sauce, folks. It's what makes your practice the go-to spot for pet care. We need to zero in on what makes you unique and how you can meet your clients' needs like nobody else. Think about your ideal client and shape your offers to hit the mark just right. Remember, we're not trying to please everyone; we're after the right ones who will appreciate the value you bring. Now, let's talk content—because it's king, queen, and the entire royal court in digital marketing. Your content has to pop and make people stop scrolling. It's not just about pretty pictures or catchy headlines; it's about telling stories that connect and educate, all while showcasing what your practice stands for. And don't forget tracking! You've got to know where your clients are coming from. Tools like CallRail can be game-changers, helping you pinpoint what's working and where to focus your marketing magic. Throughout the podcast, we've leaned on the smarts of folks like Seth Godin and Darren Shaw, and shared real-life stories, like the one about "Buy My Dad's Vet Clinic." These examples aren't just stories; they're proof that these strategies work. So, as you tune into the next episodes, remember that mastering digital marketing is totally doable. With a solid value proposition, killer content, and smart tracking, you'll be setting your practice up for success. Can't wait to share more with you—let's keep the conversation going!

The next episode of Digital Health Unplugged takes a look at interoperability in practice and empowering improved health outcomes through connecting care records. Brought to you in partnership with Oracle Health, usual host Jordan Sollof hands the reigns over to Isaac Fredericks, director of relationships at Oracle Health. He is joined by Mark Westwood, GP at The Village Green Surgery (Great North Care Record), Jocelyn Palmer, programme director at One London, and Mike Seda, executive director at Tiger Institute for Health Innovation. The panel share insights in how they are using HIE to enhance and automate data sharing workflows and what the driving factors are behind each of their projects, including improving care coordination, supporting safe patient transfers, enhancing efficiencies, and achieving better patient outcomes. Other key focus areas in the episode include implementation strategies, collaborative working across different care settings, privacy and information governance considerations, technology and adoption challenges, operational management, and insights into future projects. Digital Health would like to thank its partner for this episode, Oracle Health.  

We know that oxygen is essential for life, but did you know that there is a form of intensive oxygen therapy that can benefit your fertility? Hyperbaric oxygen therapy, or HBOT for short, is a process where a person is subject to inhale pure oxygen at a pressure above normal atmospheric pressure. In today's session we explore the benefits and why is it effective for fertility.According to research, this type of therapy has a myriad of health benefits. For starters, it facilitates a process known as angiogenesis. This involves the formation of new blood vessels from existing blood vessels, which helps blood reach further into areas/organs of the body where the previous supply of blood was low. This results in better healing, growth, and overall functioning. How does this impact your fertility? HBOT increases blood flow to the ovaries resulting in better egg, sperm and embryo quality. Aside from that, it also improves the uterine lining and eliminates toxins. According to a study conducted by the Undersea and Hyperbaric Medical Society, 32 women with unexplained infertility were entered into a randomized study over 3 years. The patients were treated in an oxygen chamber for 70 minutes, 7 days at a time. Results indicated an excellent response to the endometrium in both thickness and quality. Another study showed an improvement in mature eggs and blastocysts after undergoing the therapy during the stim phase of an IVF cycle.Tune in to get the goods on HBOT and see if it's worth exploring on your path to conception. You'll Learn: What HBOT is and how it is usedThe relationship between HBOT and fertility Health benefits of HBOT Thanks so much for listening to our podcast! If you enjoyed this episode and think others would love to hear it, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode or want to be a guest on the show? Leave a comment in the section below or visit the website to contact me!www.naturnalife.comSubscribing to The Podcast:If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts, Stitcher, Spotify, Amazon, or whatever your favorite podcast app is!Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. So if you have a minute, please leave a review on Apple Podcasts! 

Show Notes:EMS History is full of interventions we've rapidly adopted, often at great expense and withdisruption of existing processes, that later turned out to, how should I say this..... not work.Want examples? MAST and high-volume crystalloids in trauma. Mechanical compressiondevices, high-dose epinephrine, indiscriminate calcium administration in cardiac arrest. Do Ieven need to mention backboards?The next bright shiny thing promising to revolutionize cardiac arrest resuscitation is Head-UpCPR. It's certainly expensive and disruptive, but does it improve outcomes? What is theevidence?Dr. Jarvis has thoughts. He goes deep on this topic, using a recent paper on Head-Up CPR todiscuss how he evaluates new interventions for adoption. Oh, and he has thoughts on science ingeneral.Citations:1. Moore JC, Pepe PE, Scheppke KA, Lick C, Duval S, Holley J, Salverda B, Jacobs M, Nystrom P,Quinn R, et al.: Head and thorax elevation during cardiopulmonary resuscitation usingcirculatory adjuncts is associated with improved survival. Resuscitation. 2022;October;179:9–17.2. Swaminathan A: Heads Up! There is No Association with Improved Outcomes for Head UpCPR: Why We Must Read Past the Abstract.RebelEM. Available at https://rebelem.com/heads-up-there-is-no-association-with-improved-outcomes-for-head-up-cpr-why-we-must-read-past-the-abstract/.3. Mohan M, Swaminathan AK: Heads Up! Data Dredging Coming Through: Heads UpCardiopulmonary Resuscitation Does Not Improve Outcomes. Annals of Emergency Medicine.2023;February;81(2):244–5.3. Jarvis J: Not so fast: More evidence needed in head-up CPR.ems1.com. Available athttps://www.ems1.com/ems-products/cpr-resuscitaCon/arCcles/not-so-fast-more-evidence-needed-in-head-up-cpr-ZK2O7yt5eb8jryYm/. Accessed December 9, 2023.4. Moore JC: Faster Cme to automated elevation of the head and thorax duringcardiopulmonary resuscitation increases the probability of return of spontaneous circulation.ResuscitaCon. 2022;Jan(170):62–9.5. Pepe PE, Scheppke KA, Antevy PM, Crowe RP, Millstone D, Coyle C, Prusansky C, Garay S, EllisR, Fowler RL, et al.: Confirming the Clinical Safety and Feasibility of a Bundled Methodology toImprove Cardiopulmonary Resuscitation Involving a Head-Up/Torso-Up Chest CompressionTechnique. Crit Care Med. 2019;March;47(3):449–55.6. Metro Fire Chiefs: First-In Responders Providing Neuroprotective (“Heads-Up”) CPR as theStandard of Care for Emergency Medical Services Systems.NFPA. Available at https://www.nfpa.org/-/media/Files/Membership/member-secCons/Metro-Chiefs/Urban-Fire-Forum/2023/UFF23_NPCPR-PosiCon-Statement.ashx. Accessed November 4, 2023.

Please visit answersincme.com/RYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy/immunology discusses treatment intensification for adult and pediatric patients with uncontrolled asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

Please visit answersincme.com/RYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy/immunology discusses treatment intensification for adult and pediatric patients with uncontrolled asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

On today's episode, meet Dr. Robert Van Haren. Dr. Van Haren is a thoracic surgeon at the University of Cincinnati UC Health. He received his Bachelor's Degree from the University of Michigan and his Medical Degree from Michigan State. He completed his surgical training at the University of Miami Jackson Memorial, followed by a thoracic surgery fellowship at MD Anderson Cancer Center. His training was focused on minimally invasive techniques such as robotic surgery and comprehensive multidisciplinary care for complex cancers, and while in training he completed a clinical research fellowship and obtained a Master's Degree in public health at the University of Miami. His current clinical and research efforts focus on improving outcomes after surgery for lung and esophageal diseases.

In this episode of Highway to Health hosted by David Kemp, Kemp turns the spotlight onto the promising avenue of value-based care with insights from Brooke West, the Chief Commercial Officer at Carrum Health, and Christoph Dankert, the Chief Network Officer at Carrum Health. West shares a personal narrative underscoring the importance of choosing the right physician, revealing how a lack of physician expertise could have jeopardized her father's last days battling cancer. She emphasizes how Carrum Health strives to revolutionize healthcare by forging a direct link between providers and employers, negotiating upfront prospective bundles with the crème de la crème of providers to ensure quality care at optimized costs. Through a meticulous process, Carrum Health aims to enhance patient experience by easing the healthcare navigation and significantly reducing the financial burden, making quality healthcare a more accessible and less daunting prospect for all.

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable melanoma; and Identify patients for whom a neoadjuvant-adjuvant approach may be appropriate based on available clinical evidence.

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable melanoma; and Identify patients for whom a neoadjuvant-adjuvant approach may be appropriate based on available clinical evidence.

In this episode of The AI for Sales Podcast, Chad is joined by Steve Marcinuk, the General Manager of Intelligent Relations, an AI-powered PR platform. With a background in entrepreneurship and a passion for PR, Steve has built a platform that leverages AI to help companies reach the right journalists and get their stories heard.Steve discusses how AI is transforming the PR industry. Intelligent Relations uses AI to analyze data and generate personalized pitches for journalists, helping companies get their stories in front of the right audience. By leveraging AI, PR professionals can streamline their workflow, improve targeting, and achieve better results. The future of AI in PR will involve further advancements in technology and integration into existing workflows, leading to more seamless experiences and improved outcomes.KEY TAKEAWAYSIntelligent Relations uses AI to analyze data and generate personalized pitches for journalists.AI can help PR professionals streamline their workflow and improve targeting.The future of AI in PR will involve advancements in technology and integration into existing workflows.QUOTES"In PR, we have to figure out what journalists care about. PR is the way to spread the message, reach more people, amplify your reach." - Steve Marcinuk"AI will continue to improve, and it will be better integrated into workflows, creating a more seamless experience." - Steve MarcinukLearn more about Steve and connect with him in the links below:LinkedIn: https://www.linkedin.com/in/stephenmarcinuk/Website: https://intelligentrelations.com/  Learn more about AI for Sales with Chad:LinkedIn Group: https://www.linkedin.com/groups/12811259/LinkedIn Personal Page: https://www.linkedin.com/in/chadburmeister/YouTube Channel: https://www.youtube.com/@TheAIforSalesPodcastTikTok: https://www.tiktok.com/@ai4salesFacebook Page: https://www.facebook.com/theaiforsalespodcast/Twitter Page: https://twitter.com/saleshackThe AI For Sales Podcast is sponsored by our proud partners:BDR.ai | https://www.bdr.ai/TruVersity | https://www.truversity.com/

This week we delve into the world of ACHD when we review a recent important work from the multicenter INDICATOR study group assessing the impact on overall outcomes in TOF patients who have their pulmonary valve replaced. Are survival rates improved by replacement of the pulmonary valve in the TOF patient? What about the effect on ventricular tachycardia? What are the proposed mechanisms by which PVR can positively affect this critical outcomes? Are there differences between transcatheter PVR and surgical in this regard? Is there an RV volume that is the 'sweet spot' for PVR? These are amongst the many questions posed to Professor of Pediatrics and Medicine at Harvard University, Dr. Anne Marie Valente. https://doi.org/10.1016/j.jacc.2023.02.052

Today you'll learn about how spider and silkworm silk is being used to repair injured nerves, about a simple trick backed by science to get your kids to eat their vegetables, and about a new study on third trimester ultrasounds and healthier babies. Find episode transcripts here: https://curiosity-daily-4e53644e.simplecast.com/episodes/spider-silk-family-meals-pregnancy-ultrasoundsSpider Silk  “Silk from spiders and silkworms found to be a promising material to repair injured nerves.” n.a. 2023.https://www.ox.ac.uk/news/2023-04-03-silk-spiders-and-silkworms-found-be-promising-material-repair-injured-nerves-0“Peripheral nerve injuries.” Mayo Clinic. 2022.https://www.mayoclinic.org/diseases-conditions/peripheral-nerve-injuries/symptoms-causes/syc-20355631Family Meals     “Effect of Longer Family Meals on Children's Fruit and Vegetable Intake.” by Mattea Dallacker, PhD, et al. 2023.https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802987Pregnancy Ultrasounds“Giving Pregnant Women Routine Third Trimester Ultrasound Scans Could Reduce Rates of Undetected Breech Pregnancy by 71%, Enabling Better Care Before and During Labor and Improved Outcomes for Newborns.” n.a. 2023.https://www.eurekalert.org/news-releases/984712“Impact of point-of-care ultrasound and routine third trimester ultrasound on undiagnosed breech presentation and perinatal outcomes: An observational multicentre cohort study.” by Samantha Knights, et al. 2023.https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004192Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers.

While significant advances have been made overall in the treatment of multiple myeloma, the management of transplant-ineligible patients remains challenging. Patients with multiple myeloma are not cured with conventional therapy. Treatment does, however, alleviate symptoms, improve quality of life, and prolong survival. The current standard of care for multiple myeloma patients includes an anti-CD38 monoclonal antibody in either first- or second-line treatment of myeloma. CANCER BUZZ spoke to Cindy Varga, MD, Hematologist at Atrium Health's Levine Cancer Institute in Charlotte, NC. Listen as Dr. Varga discusses the positives and negatives with subcutaneous versus intravenous drugs in treating patients with multiple myeloma. “There are benefits to the patient (for subcutaneous administration), it is very fast, as quick as 5-minutes. So. there is convenience there and less side effects.” “Having patients be able to access these amazing drugs (both IV and subcutaneous) in their local infusion center, definitely helps with their up-front treatment plan. These patients are going into remissions, feeling better, and their quality of life is better on these drugs because they are so effective…” -        Cindy Varga, MD, Hematologist at Atrium Health's Levine Cancer Institute Cindy Varga, MD Hematologist Levine Cancer Institute at Atrium Health Charlotte, NC Resources: -        Leukemia & Lymphoma Society -        American Cancer Society -        Multiple Myeloma Research Foundation  This project is sponsored by Johnson & Johnson   ACCC is collaborating with The Leukemia & Lymphoma Society on this project.

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Too often, contracting is seen as a back-office function, even though many government programs are actually implemented with contracted service providers. In reality, contracting — and contracting reforms — can be a key driver of better results in human services, including for the most vulnerable families and individuals. We discuss specific steps in results-driven contracting […] The post How results-driven contracting improved outcomes for Chicago’s most vulnerable: An interview with Lisa Morrison Butler, former Commissioner, Chicago Department of Family and Support Services – Episode #202 appeared first on Gov Innovator podcast.

Please visit answersincme.com/FDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical evidence for novel Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe the latest clinical evidence for novel JAK inhibitors in the treatment of moderate-to-severe AD; Outline practical strategies to manage adverse events associated with JAK inhibitors for the treatment of moderate-to-severe AD; and Identify patients with moderate-to-severe AD who might benefit from treatment with novel JAK inhibitors.

Contextualizing care is the process of adopting your treatment approach to a patient specific life context. The failure to do so is called a contextual error, which often results in a care plan that is not likely to achieve its intended aim or produce a positive outcome. In this episode, Dr. Joe Tatta discusses how to contextualize care for improved outcomes with Gail Jensen, PT, PhD, FAPTA, Vice Provost for Learning and Assessment, Dean Emerita and Professor of Physical Therapy at Creighton University. She is internationally regarded as a scholarly expert in clinical practice, clinical reasoning, professional ethics, as well as into professional education within and outside of the physical therapy profession. Join in for more powerful information.

HealthLeaders editor Jay Asser speaks with Samir Courdy, chief informatics officer and senior vice president of informatics for Duarte, California-based City of Hope, about creating and leveraging a precision oncology learning environment on DNAnexus, called POSEIDON.

Allan Adler is the creator of #GoToEcosystems #Community and the #EcoOps Method. He is founder of Digital Bridge Partners, tech investor and in my opinion, Allan is one of the 3 freshest minds alive in sales today - ask me who the other 2 are by DM What is an ecosystem? What makes ecosystems work? On average why are partner assisted 70% larger than cold prospected deals? Allan explores 21st century#ERP Ecosystems Relationships Partnerships If you can MAKE THE TIME to the #PLXSummit in November. You can register FREE here. 5 days of #Ecosystem action leaders sharing their real world experience. https://www.plxsummit.com/  7th-11th November Contact Allan via linkedin.com/in/allanadler Website: digitalbridgepartners.com (Company) Phone: +1 425-239-8774 (Mobile) Email: allan@digitalbridgepartners.com Twitter: digitalbridgep -- What do you want your career to give you in life? How certain are you that where you're headed is where you want to take your life and career? What's your plan to make that happen? If you want to hop on a call to explore coaching and training with me https://calendly.com/marcuscauchi/let-s-explore-coaching-training Ask me about FATT Club - the best way the cut the fat from your sales and revenue function marcus@laughs-last.com 

Osteochondral autograft transplant (OAT) is often used to treat large osteochondral lesions of the talus and is generally associated with good outcomes. The addition of adjuncts such as cartilage extracellular matrix with bone marrow aspirate concentrate (ECM-BMAC) may further improve the OAT procedure but have not been thoroughly studied. We hypothesized that the placement of ECM-BMAC around the OAT graft would improve radiographic and patient-reported outcomes following OAT. In conclusion, the addition of ECM-BMAC to OAT was associated with improved imaging and clinical outcomes compared to OAT with BMAC alone.   To view the article click here.

Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don't miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.

Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don't miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.

Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don't miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.

Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don't miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.

Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don't miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.

BUFFALO, NY- May 25, 2022 – A new research paper was published in Oncotarget, entitled, “NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.” Head and neck squamous cell carcinoma (HNSCC) is a devastating disease that impairs fundamental tissues involved in respiration, phonation and digestion. HNSCC is primarily caused by exposure to either ethanol and tobacco or the human papillomavirus (HPV). Among patients with HPV+ HNSCC, there is a growing clinical demand to develop robust stratification tools to accurately identify patients with good or poor prognosis. “While oncologic outcomes for HPV+ HNSCC are generally favorable, treatment paradigms developed for HPV-negative disease burden many survivors of HPV+ HNSCC with lifelong debilitating treatment-associated side effects [10]. On the other hand, ~30% of HPV+ HNSCC patients exhibit a more aggressive disease course and suffer recurrence [11, 12].” Somatic mutations or deletions in TRAF3 or CYLD identified a subset of HPV+ HNSCC associated with improved outcome. A cross talk between canonical and non-canonical NF-κB signaling suggests that TRAF3 and CYLD affect both NF-κB pathways. “Herein, we demonstrate that an RNA-based classifier trained on tumors harboring these mutations may improve prognostic classification (Figure 3A, 3B, Figure 4B and Supplementary Figure 1).” To improve on genomic classification, researchers designed the current study to provide a foundation for development of NF-κB related, RNA based classification strategies to better identify HPV+ HNSCC patients with good or poor prognosis that could potentially aid in future efforts towards treatment personalization. “This report validates and expands on our findings that significant expression changes related to NF-κB activity occur in the subset of HPV+ HNSCC tumors marked by TRAF3 or CYLD mutations. We are planning future studies investigating the importance of ‘long-tail' mutations in the NF-κB pathway which might further illuminate the origins of NF-κB dysregulation in HPV+ HNSCC.” “Given that methods to identify patients for deintensified therapy are imperfect, our improved classifiers may serve as prognostic biomarker to help clinicians with therapeutic decisions.” DOI: https://doi.org/10.18632/oncotarget.28232 Correspondence to: Wendell G. Yarbrough and Natalia Issaeva Email: dell@med.unc.edu and natalia.isaeva@med.unc.edu Keywords: HPV, head and neck cancer, CYLD, TRAF3, NF-κB About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com.

Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.

Joel not only brings over 10 years of experience in the health and fitness field as a coach, but he also has a diverse background in leadership, consulting, life coaching and business development helping start and manage multiple small businesses and non-profit organizations. As a graduate from the University of Nevada Reno, Joel earned his bachelor's degree in Communications with a minor in Community Health Science. Joel credits his education for establishing the foundation of his coaching which focuses on the words that we say and how it affects our health and life. Throughout his career Joel has had the unique opportunity to personally interact with over 3,000 individuals as the manager of two of the largest functional fitness facilities in the United States. This gave him valuable insight into the recurring issues that people faced in both their language and their health which helped him create the techniques he now uses in his own life and in his program. Joel now works 1 on 1 with committed individuals to optimize any life goal from personal to professional by focusing on creating better language to create better outcomes.   Connect with Joel: Website: www.proclivity.co Instagram: proclivity.co Personal Instagram: @joelcochran_ Goal Setting Workshop: https://mailchi.mp/proclivity.co/goal...   Get to know more about Austin Linney: www.austinlinney.com 

Commentary by Dr. Valentin Fuster

Full speed ahead is a recipe for eventual disaster. While it can wreak havoc on anxious or panicky types to slow down AT ALL, it is ultimately what is necessary to gain traction and be able to speed up when it makes sense in life and business. It's also necessary in order to get OUT of letting feelings of anxiousness run your life instead of YOU! In today's episode we'll talk more about what slowing down to speed up actually looks like and how it translates to better success, mental health and so much more! Take a few minutes and SLOW DOWN with me! It'll be worth it!With Gratitude,xo,T________________________________________________________________________________________Theresa Lear Levine empowers and provides therapeutic support to ambitious, entrepreneurial women who feel a calling to more effectively cope with and release stress, trauma, distraction and limiting beliefs so they can create a calm, clear environment for their purpose, passion, dreams and next level goals to flourish and be manifested fully.Theresa's business, Becoming More Me, helps women become more of who they want to be as they positively transform, show up for themselves and others in greater ways, reclaim and stand tall in their power, and learn to love, accept and forgive themselves in all areas of life!✨